Sensydia has filed a notice of an exempt offering of securities to raise $8,826,449.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Sensydia is raising $8,826,449.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Anthony Arnold played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Sensydia
Sensydia is developing a portable, point-of-care hemodynamic measurement platform that uses proprietary sensor technology and machine learning to guide critical patient management decisions in heart failure, sepsis, pulmonary hypertension, and other critical diseases. The Sensydia Cardiac Performance System (CPS) is entirely non-invasive, trained to gold standard, and can be deployed in minutes in the hospital, clinic, office or at home. By making hemodynamic insights as accessible as routine blood pressure readings, CPS will enable early disease detection and improve disease management through accurate, easy-to-use, non-invasive monitoring.
To learn more about Sensydia, visit http://www.sensydia.com/
Contact:
Anthony Arnold, President and Chief Executive Officer
661-877-4670
https://www.linkedin.com/in/akarnold/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.